Novelix promoters acquire 950,000 shares via warrant conversion
Promoters of Novelix Pharmaceuticals Limited strengthened their control by acquiring 950,000 equity shares through the conversion of warrants on May 29, 2026. Srinidhi Fine Chemicals LLP acquired 800,000 shares, increasing its holding to 33.07%, while Narahari Belide acquired 150,000 shares, reaching a 3.35% stake. The company's equity share capital rose to ₹238,950,000 following the preferential allotment.
*this image is generated using AI for illustrative purposes only.
Promoters of Novelix Pharmaceuticals Limited increased their stake by acquiring 950,000 equity shares through the conversion of warrants on May 29, 2026. The acquisition, executed via a preferential allotment, significantly alters the company's shareholding pattern and strengthens promoter control. Srinidhi Fine Chemicals LLP accounted for the largest portion of this increase, acquiring 800,000 shares, while Narahari Belide acquired 150,000 shares.
The disclosures were submitted to BSE Limited on June 01, 2026, and June 02, 2026, in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filings detailed the transactions involving promoters and members of the promoter group.
Shareholding Details
The acquisition involved the conversion of warrants held by various promoter group entities. Prior to the acquisition, the company's equity share capital stood at ₹210,850,000, comprising 21,085,000 equity shares of ₹10 each. Following the allotment, the equity share capital increased to ₹238,950,000, comprising 23,895,000 equity shares of ₹10 each.
The following table outlines the changes in shareholding for the key acquirers disclosed:
| Acquirer | Shares Before | Shares Acquired | Shares After | % Holding After |
|---|---|---|---|---|
| Srinidhi Fine Chemicals LLP | 7,102,000 | 800,000 | 7,902,000 | 33.07 % |
| Narahari Belide | 650,000 | 150,000 | 800,000 | 3.35 % |
| Total | 7,752,000 | 950,000 | 8,702,000 | **36.42 % |
Historical Stock Returns for Trimurthi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.15% | -11.01% | +0.95% | +18.15% | +58.76% | +801.28% |
How will the increased promoter control influence Novelix Pharmaceuticals' strategic decision-making and future capital allocation?
What are the potential market reactions to the dilution of public shareholding caused by the preferential allotment?
Does the warrant conversion signal the promoters' confidence in the company's upcoming pipeline or financial performance?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
